Public Board of Directors papers 30 June 2022

EXECUTIVE SUMMARY

Introduction

The Integrated Performance, Quality & Finance report presents a summary dashboard that provides an overview of performance.

Safe • There were 8 incidents reported with the classification of moderate in May, details of which can be found on slide 8. All the incidents are still progressing through to full root cause analysis. No never events were reported in month.

• Slide 9 provides details of shared learning from incidents following Executive Reviews. • There are 4 Trust level risks scored at 15+. Details of these can be found on slides 12 & 13. • Safer staffing numbers have met the required acuity levels to ensure appropriate levels of safety and care for our patients. Responsive

• The 62 day cancer waiting time standard has not been met in May. Our position subject to validation is 69.9% for 62 days. The standards for Upgrade & Screening patients have also not been met with positions subject to validation of 79.3% & 50%. Within the 62 day performance we also failed to achieve the internal 24 day standard with a performance of 79.9%. All 62 and 24 day breaches are reviewed to ensure any delays are understood and plans can be implemented to mitigate any future delays . The number of patients waiting over 104 days as at the end of the month has reduced significantly from April. The majority of these patients were referred late in the pathway and often referred to the Trust over day 100. All 31 day targets and 18 week RTT standards have been achieved in May. Performance against the CWT thresholds is constantly monitored. • Referrals in May increased from April and were both higher than May 2021 and the 21/22 average. • Activity levels are now monitored against a 22/23 plan rather than a GM recovery trajectory set around 19/20 activity levels. As at month 2 Chemotherapy deliveries continue to be above plan, Radiotherapy fractions are on plan and all other points of delivery are below plan but by small margins. Effective • There were 4 cases of C-Difficile, 7 cases of E-Coli & 3 cases of MSSA in May that were deemed attributable to the Trust. No lapses in care have been identified. • There was 1 case of hospital acquired nosocomial Covid-19 infections in May. Well – Led • The trust is reporting a month 2 position of £446k deficit compared to a £439k deficit plan within the latest plan submission of an annual control total deficit of £2.6m. • The month 2 EBITDA position is a surplus of £3,777k • The cash balance is £147,055k. • Performance to month 2 is £6,670k (44%) below the proposed plan submitted to NHSE&I, reflecting the Paterson scheme and vat recovery benefits achieved against it.

30